tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Acadia Pharmaceuticals sees FY23 revenue $520M-$550M, consensus $569.2M

Sees FY23 R&D expense in the range of $235M to $255M, which includes approximately $20M of stock-based compensation expense and SG&A expense in the range of $360M to $380M, which includes approximately $45M of stock-based compensation expense.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on ACAD:

Disclaimer & DisclosureReport an Issue

1